GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Intrinsic Value: Projected FCF

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Frazier Lifesciences Acquisition Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-15), Frazier Lifesciences Acquisition's Intrinsic Value: Projected FCF is $0.00. The stock price of Frazier Lifesciences Acquisition is $9.87. Therefore, Frazier Lifesciences Acquisition's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Frazier Lifesciences Acquisition's Intrinsic Value: Projected FCF or its related term are showing as below:

FLAC's Price-to-Projected-FCF is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.87
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Frazier Lifesciences Acquisition Intrinsic Value: Projected FCF Historical Data

The historical data trend for Frazier Lifesciences Acquisition's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frazier Lifesciences Acquisition Intrinsic Value: Projected FCF Chart

Frazier Lifesciences Acquisition Annual Data
Trend Dec20 Dec21
Intrinsic Value: Projected FCF
- -

Frazier Lifesciences Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Frazier Lifesciences Acquisition's Intrinsic Value: Projected FCF

For the Shell Companies subindustry, Frazier Lifesciences Acquisition's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frazier Lifesciences Acquisition's Price-to-Projected-FCF Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Frazier Lifesciences Acquisition's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Frazier Lifesciences Acquisition's Price-to-Projected-FCF falls into.



Frazier Lifesciences Acquisition Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Frazier Lifesciences Acquisition  (NAS:FLAC) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Frazier Lifesciences Acquisition's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=9.87/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Frazier Lifesciences Acquisition Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Frazier Lifesciences Acquisition's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
601 Union Street, Two Union Square, Suite 3200, Seattle, WA, USA, 9810
Frazier Lifesciences Acquisition Corp is a blank check company.
Executives
David Joseph Topper director, officer: Chief Financial Officer C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 32ND FLOOR, NEW YORK NY 10055
Krishna R Polu director C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Robert Jr. Baltera director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830